TY - JOUR
T1 - SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma
T2 - Phase 1 study
AU - Morgensztern, Daniel
AU - Johnson, Melissa
AU - Rudin, Charles M.
AU - Rossi, Michael
AU - Lazarov, Mirella
AU - Brickman, Daniel
AU - Fong, Abraham
N1 - Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2020/7
Y1 - 2020/7
N2 - Objectives: This phase 1 study investigated safety/tolerability, pharmacokinetics, and preliminary efficacy of SC-002, a delta-like ligand 3-directed antibody-drug conjugate, in advanced small cell lung cancer and large cell neuroendocrine carcinoma. Materials and methods: Eligible patients received SC-002 at 1 of 7 dose levels during the dose-escalation portion of the study. Results: Thirty-five enrolled patients received ≥1 dose of SC-002. Twenty-three (66%) patients experienced serious adverse events (AEs), 37% considered related to SC-002. Grade 3/4 AEs occurred in 21 (60%) and 2 (6%) patients; the most common were effusion and hypoalbuminemia. One grade 5 AE occurred in 1 patient. Five (14%) patients achieved a partial response and no patients achieved a complete response. Conclusion: SC-002 treatment was associated with systemic toxicity and limited efficacy.
AB - Objectives: This phase 1 study investigated safety/tolerability, pharmacokinetics, and preliminary efficacy of SC-002, a delta-like ligand 3-directed antibody-drug conjugate, in advanced small cell lung cancer and large cell neuroendocrine carcinoma. Materials and methods: Eligible patients received SC-002 at 1 of 7 dose levels during the dose-escalation portion of the study. Results: Thirty-five enrolled patients received ≥1 dose of SC-002. Twenty-three (66%) patients experienced serious adverse events (AEs), 37% considered related to SC-002. Grade 3/4 AEs occurred in 21 (60%) and 2 (6%) patients; the most common were effusion and hypoalbuminemia. One grade 5 AE occurred in 1 patient. Five (14%) patients achieved a partial response and no patients achieved a complete response. Conclusion: SC-002 treatment was associated with systemic toxicity and limited efficacy.
KW - Antibody-drug conjugate
KW - Delta-like ligand 3
KW - Large cell neuroendocrine carcinoma
KW - Pyrrolobenzodiazepine
KW - SC-002
KW - Small cell lung cancer
UR - https://www.scopus.com/pages/publications/85085144622
U2 - 10.1016/j.lungcan.2020.04.017
DO - 10.1016/j.lungcan.2020.04.017
M3 - Article
C2 - 32438272
AN - SCOPUS:85085144622
SN - 0169-5002
VL - 145
SP - 126
EP - 131
JO - Lung Cancer
JF - Lung Cancer
ER -